HCAR2 recombinant proteins and antibodies

Hydroxycarboxylic Acid Receptor 2 (HCAR2) is a G-protein coupled receptor that is widely expressed in adipose tissue, skeletal muscle, heart, and immune cells. It detects short-chain fatty acids and other hydroxycarboxylic acids, playing a role in regulating energy metabolism, inflammation, immune function, and neurological activity. The activation of the HCAR2 receptor is closely related to a variety of physiological functions, including fatty acid metabolism, glucose metabolism, and anti-inflammatory effects. As a result, HCAR2 is considered a potential therapeutic target for metabolic diseases, cardiovascular diseases, and inflammation-related disorders.

One of the key biological functions of HCAR2 is its role in regulating the body’s energy balance. Studies have shown that HCAR2 can regulate lipid metabolism in adipocytes, improve insulin sensitivity, and inhibit fat accumulation, making it an important target for treating metabolic diseases such as obesity and type 2 diabetes. Additionally, the activation of HCAR2 has been shown to reduce tissue damage caused by chronic inflammation, highlighting its potential applications in cardiovascular diseases and immune disorders.

Currently, drug development targeting HCAR2 is focused on metabolic diseases, cardiovascular diseases, and inflammatory diseases. Several companies are exploring the development of HCAR2 agonists, which can stimulate the HCAR2 receptor to regulate fatty acid metabolism, improve insulin sensitivity, and exert anti-inflammatory effects. Preclinical studies have shown that HCAR2 agonists can improve the symptoms of metabolic diseases such as obesity and type 2 diabetes.

In terms of industry positioning, multiple biopharmaceutical companies have entered the field of HCAR2-related drug development. Particularly in the treatment of metabolic diseases, some companies are developing small-molecule HCAR2 agonists, which are expected to help alleviate conditions such as obesity, diabetes, and cardiovascular diseases by enhancing insulin sensitivity, improving lipid metabolism, and suppressing chronic inflammation. Additionally, some companies are exploring the potential of HCAR2 in immune modulation and anti-inflammatory treatments, particularly in autoimmune diseases and cardiovascular diseases.
Overall, HCAR2, as a multifunctional target, holds broad clinical potential, especially in the treatment of metabolic and cardiovascular diseases. With ongoing research, more innovative drugs targeting HCAR2 may emerge in the future, providing new hope for treating these related diseases.

To assist in the development of drugs targeting HCAR2, DIMA BIOTECH can now provide full-length HCAR2 recombinant membrane protein developed by its nanodisc membrane protein platform. HCAR2 nanodisc is an optimal solution for screening small molecules targeting HCAR2 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a HCAR2 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.